Ridgecrest Wealth Partners’s Rein Therapeutics RNTX Stock Holding History

Ridgecrest Wealth Partners’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500	Closed	-$2K	–	102
2022 Q3	$2K	Hold	500	–	–	﹤0.01%	97
2022 Q2	$3K	Hold	500	–	–	﹤0.01%	105
2022 Q1	$5K	Hold	500	–	–	﹤0.01%	108
2021 Q4	$6K	Hold	500	–	–	﹤0.01%	121
2021 Q3	$10K	Hold	500	–	–	0.01%	113
2021 Q2	$13K	Hold	500	–	–	0.01%	108
2021 Q1	$14K	Buy	+500	New	+$17.1K	0.01%	92

Other funds holding RNTX

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Ridgecrest Wealth Partners's RNTX Position: Q4 2022 in Review

Ridgecrest Wealth Partners sold out of Rein Therapeutics (RNTX) in Q4 2022, closing a stake of 500 shares — an estimated $2K sold.

Ridgecrest Wealth Partners first reported a position in RNTX in Q1 2021 and held it in 7 quarters. The position peaked at $14K in Q1 2021. 19 funds tracked by Wall St. Rank hold RNTX as of Q4 2022.

Ridgecrest Wealth Partners reported no remaining Rein Therapeutics position as of Q4 2022 after selling out during the quarter.
Ridgecrest Wealth Partners sold 500 Rein Therapeutics shares in Q4 2022, an estimated $2K.
Ridgecrest Wealth Partners first reported a position in Rein Therapeutics in Q1 2021 and held it in 7 quarters.
Ridgecrest Wealth Partners's Rein Therapeutics position peaked at $14K in Q1 2021.
19 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2022.

Based on Ridgecrest Wealth Partners's 13F filing for Q4 2022, filed 26 Jan 2023.